2359 GMT - Insilico offers one of the clearest tests of whether AI can expand pharma innovation beyond faster molecule design, Citi analysts. They start coverage with a buy/high-risk rating. Insilico has sustained preclinical candidate generation since 2021 across multiple therapeutic areas, supporting the repeatability of its AI-discovery process. The 15 partnerships with global firms it has disclosed have an aggregate headline contract value exceeding $11 billion and suggest it can convert hypotheses into development assets and commercial transactions at scale. Of the various clinical assets on track to validate Insilico's AI-driven drug design, Citi sees rentosertib--the first AIDD candidate in Phase III--as the biggest valuation catalyst. It sets a HK$85 target on the stock, which closed at HK$44.96.